Anzeige
Mehr »
Login
Mittwoch, 24.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
SolarBank - Solarenergie...
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
277 Leser
Artikel bewerten:
(2)

Prostate Cancer Pipeline H1 2017 Therapeutic Key Players 3-V Biosciences Inc, 4SC AG, Actinium Pharmaceuticals Inc and Advaxis Inc, Says a New Research Report at RnRMarketResearch.com

PUNE, India, July 11, 2017 /PRNewswire/ --

Prostate Cancer Pipeline Review, H1 2017 is new research report highlights details analysis includes 1845 pages with latest updates, Drug Profiles, Key players, Table of Contents, List of Tables, List of Figures.

Prostate cancer is a form of cancer that affects men and starts off in the prostate gland. Prostate cancer usually occurs in older men. Symptoms include trouble urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips or thighs, bone pain and erectile dysfunction. Predisposing factors include age, family history and obesity. Treatment includes surgery, chemotherapy and radiation therapy.

Complete report on Prostate Cancer - Pipeline Review, H1 2017 spread across 1845 pages is available at http://www.rnrmarketresearch.com/prostate-cancer-pipeline-review-h1-2017-market-report.html .

Prostate Cancer - Pipeline Review, H1 2017, provides an overview of the Prostate Cancer (Oncology) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 18, 98, 108, 6, 247, 35 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 11, 15, 58 and 20 molecules, respectively.

Order a copy of this research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=1126467 .

Main key players of Prostate Cancer Pipeline are 3-V Biosciences Inc, 4SC AG, AB Science SA, AbbVie Inc, Actinium Pharmaceuticals Inc, ADC Therapeutics Sarl, Addex Therapeutics Ltd, Aduro BioTech Inc, Advanced Accelerator Applications SA, Advanced Cancer Therapeutics LLC, Advantagene Inc, Advaxis Inc, Aeglea BioTherapeutics Inc, Aeolus Pharmaceuticals Inc, Aeterna Zentaris Inc, Akshaya Bio Inc, Alchemia Ltd, Alethia Biotherapeutics Inc, Alissa Pharma, Almac Discovery Ltd, Ambrx Inc, Amgen Inc, Anavex Life Sciences Corp, AndroScience Corp, AnGes MG Inc, AntiCancer Inc, Antigen Express Inc, Antisense Therapeutics Ltd, Apcure SAS, Aphios Corp, APIM Therapeutics AS, Aptevo Therapeutics Inc, Aptose Biosciences Inc, ARMO Biosciences Inc, Armour Therapeutics Inc, Arno Therapeutics Inc, ArQule Inc, Arrien Pharmaceuticals LLC, Arrowhead Pharmaceuticals Inc, Arvinas Inc, Asana BioSciences LLC, Asieris Pharmaceuticals Co Ltd, Astellas Pharma Inc, AstraZeneca Plc, Aurigene Discovery Technologies Ltd, Avipep Pty Ltd, Bavarian Nordic A/S, Bayer AG more..

The pipeline guide provides a snapshot of the global therapeutic landscape of Prostate Cancer (Oncology). The pipeline guide reviews pipeline therapeutics for Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.

Related reports on Cancer Therapeutics

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2017

Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The Key players are 4SC AG, AbbVie Inc, Actuate Therapeutics Inc, Adaptimmune Therapeutics Plc, Aduro BioTech Inc, Advanced Cancer Therapeutics LLC, Advenchen Laboratories LLC, Affitech A/S, Alethia Biotherapeutics Inc, Alkermes Plc, Altor BioScience Corp, Ambrx Inc, Amgen Inc, Ampio Pharmaceuticals Inc, Apac Biotech Pvt Ltd and more others.

Explore more reports of Therapeutics Market Research at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics

About Us:

RnRMarketResearch.com is your one stop market research and industry analysis reports' library providing business data and intelligence information on thousands of micro markets with global as well as regional coverage. Category focused research, country reports, company profiles, regional and global industry profiles and guides to premium reports offering extensive coverage of other 20+ industries are all available in our library of syndicated market research reports.

Contact:
Ritesh Tiwari
2nd Floor, Metropole,
Bund Garden Road,
Pune - 411001, India
Tel: +1-888-391-5441
E-mail: sales@rnrmarketresearch.com


Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.